Lomasney J W, Leeb-Lundberg L M, Cotecchia S, Regan J W, DeBernardis J F, Caron M G, Lefkowitz R J
J Biol Chem. 1986 Jun 15;261(17):7710-6.
alpha 1-Adrenergic receptors from a cultured smooth muscle cell line (DDT1 MF-2) have been solubilized with digitonin and purified to apparent homogeneity by sequential chromatography on a biospecific affinity support (Sepharose-A55453 (4-amino-6,7-dimethoxy-2-[4-[5-(4-amino-3-phenyl) pentanoyl]-1-piperazinyl]-quinazoline), an alpha 1 receptor-selective antagonist), a wheat germ agglutinin-agarose gel, and a high performance steric exclusion liquid chromatography column. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and autoradiography of iodinated purified receptor preparations reveals a peptide with an apparent Mr = 80,000 that co-migrates with the peptide labeled by the specific alpha 1-adrenergic receptor photoaffinity probe 4-amino-6,7-dimethoxy-2-[4-[5-(4-azido-3-[125I]iodophenyl)pentanoyl] -1-piperazinyl] quinazoline. The specific activity (approximately 13,600 pmol of ligand binding/mg of protein) of purified receptor preparations is consistent with that expected for a pure peptide of Mr = 80,000 containing a single ligand binding site. Overall yields approximate 14% of initial crude particulate binding. The purified receptor preparations bind agonist and antagonist ligands with appropriate alpha 1-adrenergic specificity, stereoselectivity, and affinity. Peptide maps of the pure alpha 1-adrenergic receptor and the pure human platelet alpha 2-adrenergic receptor (Regan, J.W., Nakata, H., DeMarinis, R.M., Caron, M.G., and Lefkowitz, R.J. (1986) J. Biol. Chem. 261, 3894-3900) using several different proteases suggest that these two receptors show little if any structural homology.
来自培养的平滑肌细胞系(DDT1 MF - 2)的α1 - 肾上腺素能受体已用洋地黄皂苷溶解,并通过在生物特异性亲和支持物(琼脂糖 - A55453(4 - 氨基 - 6,7 - 二甲氧基 - 2 - [4 - [5 - (4 - 氨基 - 3 - 苯基)戊酰基] - 1 - 哌嗪基] - 喹唑啉),一种α1受体选择性拮抗剂)、麦胚凝集素 - 琼脂糖凝胶和高效空间排阻液相色谱柱上的连续色谱法纯化至表观均一性。十二烷基硫酸钠 - 聚丙烯酰胺凝胶电泳和碘化纯化受体制剂的放射自显影显示出一条表观分子量为80,000的肽,它与由特异性α1 - 肾上腺素能受体光亲和探针4 - 氨基 - 6,7 - 二甲氧基 - 2 - [4 - [5 - (4 - 叠氮基 - 3 - [125I]碘苯基)戊酰基] - 1 - 哌嗪基]喹唑啉标记的肽共迁移。纯化受体制剂的比活性(约13,600 pmol配体结合/ mg蛋白质)与预期的含有单个配体结合位点、分子量为80,000的纯肽一致。总产率约为初始粗颗粒结合量的14%。纯化的受体制剂以适当的α1 - 肾上腺素能特异性、立体选择性和亲和力结合激动剂和拮抗剂配体。使用几种不同蛋白酶对纯α1 - 肾上腺素能受体和纯人血小板α2 - 肾上腺素能受体(里根,J.W.,中田,H.,德马里尼斯,R.M.,卡隆,M.G.,和莱夫科维茨,R.J.(1986年)《生物化学杂志》261,3894 - 3900)进行的肽图谱分析表明,这两种受体几乎没有结构同源性。